ABCELLERA BIOLOGICS Financial Flexibility Index
ABCELLERA BIOLOGICS financial flexibility index. ABCELLERA BIOLOGICS (8QQ) has a Financial Flexibility Index of 0.07x as of June 2026. Free cash flow of €28.05 Million (operating CF €25.92 Million minus capex €2.13 Million) represents 0% of total liabilities (€411.56 Million). See cash generation quality of ABCELLERA BIOLOGICS to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of ABCELLERA BIOLOGICS (2021–2025)
Financial flexibility index of ABCELLERA BIOLOGICS from 2021 to 2025. Historical Financial Flexibility Index trend for ABCELLERA BIOLOGICS across 5 annual periods. Check ABCELLERA BIOLOGICS (8QQ) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
ABCELLERA BIOLOGICS Financial Flexibility Index by Year (2021–2025)
ABCELLERA BIOLOGICS financial flexibility index by year from 2021 to 2025. Year-by-year free cash flow to debt coverage for ABCELLERA BIOLOGICS. For the full cash flow conversion analysis, see how efficiently does ABCELLERA BIOLOGICS generate cash.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.23x | €-88.52 Million | €-131.29 Million | €390.05 Million | ▼ -129.1% |
| 2024 | -0.10x | €-30.16 Million | €-108.56 Million | €304.47 Million | ▼ -198.9% |
| 2023 | 0.10x | €33.63 Million | €-43.88 Million | €335.78 Million | ▼ -91.2% |
| 2022 | 1.14x | €350.02 Million | €277.36 Million | €307.63 Million | ▲ +9.9% |
| 2021 | 1.03x | €303.04 Million | €244.58 Million | €292.84 Million | — |